Cargando…

Base-edited CAR T cells for combinational therapy against T cell malignancies

Targeting T cell malignancies using chimeric antigen receptor (CAR) T cells is hindered by ‘T v T’ fratricide against shared antigens such as CD3 and CD7. Base editing offers the possibility of seamless disruption of gene expression of problematic antigens through creation of stop codons or eliminat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Georgiadis, Christos, Rasaiyaah, Jane, Gkazi, Soragia Athina, Preece, Roland, Etuk, Aniekan, Christi, Abraham, Qasim, Waseem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632682/ https://www.ncbi.nlm.nih.gov/pubmed/34035409 http://dx.doi.org/10.1038/s41375-021-01282-6

Ejemplares similares

CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity
por: Preece, Roland, et al.
Publicado: (2020)

Cytosine Deaminase Base Editing to Restore COL7A1 in Dystrophic Epidermolysis Bullosa Human: Murine Skin Model
por: Naso, Gaetano, et al.
Publicado: (2023)

Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment
por: Gkazi, Soragia Athina, et al.
Publicado: (2022)

Genome editing of therapeutic T cells
por: Qasim, Waseem
Publicado: (2021)

Genome-Edited T Cell Therapies
por: Delhove, Juliette M. K. M., et al.
Publicado: (2017)

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
por: Qasim, Waseem
Publicado: (2023)

Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2021)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
por: Moretti, Federico A., et al.
Publicado: (2021)

Author Correction: Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
por: Moretti, Federico A., et al.
Publicado: (2021)

The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020)

Automated generation of gene-edited CAR T cells at clinical scale
por: Alzubi, Jamal, et al.
Publicado: (2020)

IMMU-23. Novel gene-edited CAR-T cell therapy against Diffuse Intrinsic Pontine Glioma
por: Balakrishnan, Ilango, et al.
Publicado: (2022)

Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
por: Walti, Carla S., et al.
Publicado: (2021)

Clinical T Cell Receptor Repertoire Deep Sequencing and Analysis: An Application to Monitor Immune Reconstitution Following Cord Blood Transplantation
por: Gkazi, Athina Soragia, et al.
Publicado: (2018)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Lentiviral Vector Production Titer Is Not Limited in HEK293T by Induced Intracellular Innate Immunity
por: Ferreira, Carolina B., et al.
Publicado: (2019)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
por: Zhang, Angela Q., et al.
Publicado: (2023)

Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
por: Glaser, Viktor, et al.
Publicado: (2023)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies
por: Jung, In-Young, et al.
Publicado: (2018)

A versatile system for rapid multiplex genome-edited CAR T cell generation
por: Ren, Jiangtao, et al.
Publicado: (2017)

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
por: Dimitri, Alexander, et al.
Publicado: (2022)

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
por: Klampatsa, Astero, et al.
Publicado: (2020)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells
por: Salisbury-Ruf, Christi T., et al.
Publicado: (2021)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c12dq6gb0oc8g4l63ph8r09j93